MedTrace Logo

Efficacy of the "Consilium" Smartphone App for Detecting Symptoms and Treatment Side Effects in Cancer Patients

NCT03578731 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2022-02-01

No results posted yet for this study

Summary

The study investigates the influence of the use of a Smartphone App, on changes in general well-being and the occurrence of symptoms during a tumor therapy. With this documentation, medical professionals should be enabled to judge the influence of symptoms on quality of life during different time periods, between planed visits on site.

Conditions

  • Telemedicine
  • eHealth

Interventions

DEVICE

app

The app is used to record the study parameters for a period of 90 days. The following measures are used for data collection: * Interview during regular consultation with doctor * Web-App for gathering doctors data * "Consilium" Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message. * Well-being through a patient rating on a visual analog scale * Registration of symptoms and treatment side effects is done through the app After completion of the study patients will be questioned according to: • Usability and usefulness of the Smartphone app

Sponsors & Collaborators

  • Stiftung Swiss Tumor Institute

    collaborator OTHER

  • OnkoZentrum Zürich AG

    lead OTHER

Principal Investigators

  • Andreas Trojan, Prof. Dr. med. · OnkoZentrum Zürich AG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2020-10-10
Completion
2020-10-10

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03578731 on ClinicalTrials.gov